Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 


       2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

Ondansetron Hcl  Taj API

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  

Ondansetron Hcl Manufacturers in India Suppliers Ondansetron Hcl Dossage Exporters Distributors Ondansetron Hcl api active pharmaceuticals ingredients Ondansetron Hcl manufacturers Side Effects bulk drugs raw material Dossage Ondansetron Hcl companies Side Effects Dossage Importers Ondansetron Hcl Dossage Ondansetron Hcl Exporters Ondansetron Hcl exporters Dossage FDA Dossage Ondansetron Hcl Dossage DMF Symptoms Dossage Generic Taj Pharmaceuticals Ltd.

active pharmaceutical ingredients suppliers pharmaceutical Ondansetron Hcl manufacturing pharmaceutical drugs pharmaceutical intermediates Ondansetron Hcl pharmaceutical chemicals pharmaceutical raw materials Ondansetron Hcl active pharmaceutical ingredients Ondansetron Hcl committee active pharmaceutical ingredients manufacturer Ondansetron Hcl Active Pharmaceutical Ingredients manufacturer Ondansetron Hcl exporter drug ingredients pharmaceuticals

Pharmaceuticals API Manufacturer Ondansetron Hcl, Ondansetron Hcl manufacturer India, Ondansetron Hcl product, Ondansetron Hcl products, Api preparation, Certificate of Analysis API manufacturer product, Ondansetron Hcl anti ulcer product, Certificate of Origin COA Ondansetron Hcl COS Ondansetron Hcl, pharmaceutical generic, pharmaceutical drug, medical, Ondansetron Hcl pharma healthcare, pharma patents, contract MSDS manufacturing Trader Ondansetron Hcl pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Ondansetron Hcl expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Ondansetron Hcl DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Ondansetron Hcl ingredients, api, HIV Ondansetron Hcl, tablets, capsules, syrup & protein Ondansetron Hcl powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Ondansetron Hcl gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Ondansetron Hcl WHO, UKMHRA Approval

   PRODUCT LIST
   Home
   API >>>
   Pharmaceuticals API List
   Chemicals
   Manufacturing
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us
 

Ondansetron-Hcl img.





















 



 






 

 

HOME >> API >> API List 3 >> Ondansetron Hcl >> Dosage

Ondansetron Hcl CAS Registry Number 103639-04-9

DOSAGE
Ondansetron Hcl CAS Registry Number 103639-04-9

The recommended adult oral dosage of Ondansetron Hcl is 24 mg given as three 8-mg tablets administered 30 minutes before the start of single-day highly emetogenic chemotherapy, including cisplatin ≥ 50 mg/m. Multiday, single-dose administration of a 24 mg dosage has not been studied.

Pediatric Use: There is no experience with the use of a 24 mg dosage in pediatric patients.

Geriatric Use: The dosage recommendation is the same as for the general population.

Prevention of Nausea and Vomiting Associated With Moderately Emetogenic Cancer Chemotherapy: The recommended adult oral dosage is one 8-mg Ondansetron Hcl Tablet or one 8-mg Ondansetron Hcl Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of Ondansetron Hcl Oral Solution given twice a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with a subsequent dose 8 hours after the first dose. One 8-mg Ondansetron Hcl Tablet or one 8-mg Ondansetron Hcl Tablet or 10 mL (2 teaspoonfuls equivalent to 8 mg of ondansetron) of Ondansetron Hcl Oral Solution should be administered twice a day (every 12 hours) for 1 to 2 days after completion of chemotherapy.

Pediatric Use: For pediatric patients 12 years of age and older, the dosage is the same as for adults. For pediatric patients 4 through 11 years of age, the dosage is one 4-mg Ondansetron Hcl Tablet or one 4-mg Ondansetron Hcl Tablet or 5 mL (1 teaspoonful equivalent to 4 mg of ondansetron) of Ondansetron Hcl Oral Solution given 3 times a day. The first dose should be administered 30 minutes before the start of emetogenic chemotherapy, with subsequent doses 4 and 8 hours after the first dose. One 4-mg Ondansetron Hcl Tablet or one 4-mg Ondansetron Hcl Tablet or 5 mL (1 teaspoonful equivalent to 4 mg of ondansetron) of Ondansetron Hcl Oral Solution should be administered 3 times a day (every 8 hours) for 1 to 2 days after completion of chemotherapy.

Geriatric Use: The dosage is the same as for the general population.

Dosage Adjustment for Patients With Impaired Renal Function: The dosage recommendation is the same as for the general population. There is no experience beyond first-day administration of ondansetron.

Dosage Adjustment for Patients With Impaired Hepatic Function: In patients with severe hepatic impairment (Child-Pugh2 score of 10 or greater), clearance is reduced and apparent volume of distribution is increased with a resultant increase in plasma half-life. In such patients, a total daily dose of 8 mg should not be exceeded.

Information Associated with Product:
DRUG DESCRIPTION
DOSAGE >>
SIDE EFFECTS
PRECAUTIONS
INTERACTION
CONSUMER INFORMATION
 
 
PDF DOWNLOAD WORD DOCUMENT
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo
 

Ondansetron Hcl

Copyright Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap

Investor Relations    Feedback     Contact Worldwide    Sitemap
 

taj group logo
2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited  products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.